How Much Does Evenity (Romosozumab) Cost in Delaware in 2026?

Delaware Retail Pricing: What You Pay Without Insurance

The average cash-pay price for Evenity across Delaware retail pharmacies in 2026 is $1,825 per monthly dose, matching the Amgen/UCB wholesale acquisition cost. Each dose consists of two prefilled syringes (105 mg/1.17 mL each) administered as a pair of subcutaneous injections during one visit. Twelve consecutive monthly doses make a complete course, putting the total cash price at $21,900.

Delaware has three counties and a limited number of specialty pharmacies that stock Evenity. Pricing variation is minimal because the drug moves through specialty distribution rather than standard retail channels. Most patients receive injections at a physician's office or infusion center rather than filling a retail prescription, which means the "buy and bill" model (where the provider purchases the drug and bills insurance) is far more common than patients picking up cartons themselves 1.

Patients paying out of pocket should request the provider's acquisition cost directly. Some rheumatology and endocrinology offices in Wilmington and Newark negotiate group purchasing discounts that occasionally shave 3-5% off list.

Delaware Medicaid Coverage for Romosozumab

Delaware Medicaid covers Evenity with prior authorization. The PA criteria typically require documentation of severe osteoporosis, defined as a T-score of -2.5 or below at the hip or spine with a prior fragility fracture, or a T-score below -3.0 without fracture history. Step therapy usually mandates failure of, intolerance to, or contraindication for at least one oral bisphosphonate (alendronate or risedronate) before approval.

The approval process through the Delaware Division of Medicaid and Medical Assistance takes 5-15 business days for standard requests. Urgent requests tied to recent vertebral fractures may be expedited. Once approved, coverage extends for the full 12-month treatment course without re-authorization at mid-point.

The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months 2. This data point supports the Medicaid medical necessity argument: romosozumab is not simply an alternative to bisphosphonates but a sequenced anabolic-first strategy for patients at imminent fracture risk.

Delaware Medicaid enrolled approximately 283,000 beneficiaries as of early 2026, and claims data suggests fewer than 200 Evenity courses are authorized annually statewide. This reflects both the narrow indication and the documentation burden of prior authorization.

Commercial Insurance Coverage in Delaware

The major commercial payers operating in Delaware (Highmark BCBS Delaware, Aetna, Cigna, and UnitedHealthcare) all include Evenity on specialty tier formularies with prior authorization and step therapy requirements. Typical cost-sharing after PA approval:

Preferred specialty tier copay ranges from $150-$500 per fill depending on plan design. Coinsurance plans (common in high-deductible arrangements) assign 20-30% after deductible, which on a $1,825 drug means $365-$548 per dose before any manufacturer assistance.

The Endocrine Society's 2020 clinical practice guideline recommends anabolic therapy first (teriparatide, abaloparatide, or romosozumab) for patients at very high fracture risk, followed by antiresorptive therapy 3. Citing this guideline in appeals can overturn initial denials based on step-therapy requirements for bisphosphonate trials.

Dr. Felicia Cosman, writing in the Journal of Bone and Mineral Research, stated: "The treat-to-target approach in osteoporosis means starting with the most potent agent in those at highest risk, not reserving anabolic therapy as salvage" 4. Delaware insurers increasingly accept this logic when the prescriber documents FRAX 10-year major osteoporotic fracture probability exceeding 20%.

How the Amgen/UCB Savings Card Works in Delaware

The Evenity Together savings card, sponsored by Amgen and UCB, provides up to $25 to 000 in annual copay assistance for commercially insured patients. The card covers the patient's out-of-pocket cost (copay or coinsurance) for each monthly injection. Eligibility requirements: the patient must have commercial insurance that covers Evenity, reside in the United States, and not be enrolled in any federal or state government healthcare program (Medicare, Medicaid, Tricare, VA).

For a Delaware patient with a $300 monthly specialty copay, the savings card effectively reduces cost to $0 for all 12 doses. The $25,000 annual cap exceeds the total list price of a full course ($21,900), so even patients with 30% coinsurance on high-deductible plans are fully covered.

Enrollment requires calling 1-888-EVENITY or registering online. The card activates within 48 hours. Providers billing under buy-and-bill can apply the card to the patient responsibility portion after insurance adjudication. Specialty pharmacies processing home-delivery can apply it at the point of dispensing.

Patients on Medicare Part B (which covers physician-administered drugs) are ineligible for the manufacturer card. However, Medicare Part B typically assigns Evenity to the J-code billing pathway with 20% coinsurance after the Part B deductible, making the monthly out-of-pocket approximately $365. Medicare Supplement (Medigap) plans often cover this remainder.

Compounded Romosozumab in Delaware: Legal Status and Practical Reality

Compounded romosozumab is technically accessible in Delaware through licensed 503A compounding pharmacies operating under state pharmacy board oversight. Delaware Board of Pharmacy regulations permit 503A pharmacies to compound patient-specific prescriptions for drugs that are not commercially available in the exact form needed or when a patient has a documented medical need for a compounded version.

Here is the practical issue: romosozumab is a monoclonal antibody (sclerostin inhibitor) produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells. True biologic compounding requires aseptic manufacturing capabilities that most 503A pharmacies lack. No Delaware 503A pharmacy currently advertises compounded romosozumab at scale.

The FDA's position on compounding biologics remains restrictive. The Biologics Price Competition and Innovation Act (BPCIA) pathway governs biosimilar and interchangeable biologic approval, and the agency has issued warning letters to compounders attempting to produce monoclonal antibodies outside this framework 5.

While the legal pathway exists on paper, patients should not expect a functional compounded romosozumab option in Delaware at this time. The $0/month figure sometimes cited for compounded biologics reflects theoretical pricing, not available product.

Telehealth Prescribing of Evenity in Delaware

Delaware permits telehealth prescribing of Evenity. The Delaware Telehealth Act (Title 24, Chapter 17, Subchapter IX) allows licensed physicians to establish patient-provider relationships via synchronous audio-video communication. A prescriber can evaluate bone density results, fracture history, and cardiovascular risk factors remotely, then transmit the prescription to a specialty pharmacy or arrange buy-and-bill at a local infusion site.

The practical workflow: a patient in Sussex County with limited access to endocrinology or rheumatology specialists (concentrated in New Castle County around Wilmington) can consult with an osteoporosis specialist via telehealth. The specialist reviews the DEXA scan, orders labs (calcium, 25-OH vitamin D, PTH, renal function), assesses cardiovascular history per the boxed warning requirements, and prescribes Evenity. Monthly injections are then administered at a local primary care office or visiting nurse service.

This model matters because Delaware has only 9 board-certified endocrinologists per the ABIM directory, creating geographic access gaps in Kent and Sussex counties.

Comparing Romosozumab Cost to Alternative Osteoporosis Agents in Delaware

Understanding where Evenity sits in the cost hierarchy helps frame whether the price premium is justified for a given patient's fracture risk:

Generic alendronate (Fosamax) costs $4-$15 per month. Denosumab (Prolia) costs approximately $1,600-$1,800 per six-month injection ($267-$300/month equivalent). Teriparatide (Forteo) runs $3,400-$3,800 per month at retail, though authorized generics have brought some prices below $2,000/month. Abaloparatide (Tymlos) costs approximately $2,800-$3,200 per month 6.

Romosozumab at $1,825/month for 12 months is actually less expensive per month than teriparatide, with a shorter treatment duration (12 months vs. 24 months for teriparatide/abaloparatide). The total course cost of $21,900 compares to $81,600-$91,200 for a 24-month Forteo course at retail pricing.

The ARCH trial showed romosozumab-to-alendronate reduced clinical fractures by 27% vs. alendronate alone at 24 months (HR 0.73 to 95% CI 0.61-0.87, P<0.001) 2. The FRAME trial (N=7,180) demonstrated 73% reduction in new vertebral fractures at 12 months with romosozumab vs. placebo (0.5% vs. 1.8%, P<0.001) 7.

Cardiovascular Safety Considerations and Cost Implications

The boxed warning on Evenity's label notes increased risk of myocardial infarction, stroke, and cardiovascular death observed in the ARCH trial. Romosozumab-treated patients experienced 2.5% serious cardiovascular events vs. 1.9% in the alendronate group over the study period 2.

This safety signal directly affects cost considerations in Delaware for two reasons. First, insurers may deny coverage for patients with established cardiovascular disease, recent MI, or recent stroke within the past year. Denials on cardiovascular grounds are generally not overturnable through peer-to-peer review. Second, the prescribing physician must document cardiovascular risk assessment, adding a visit cost (EKG, cardiology clearance in borderline cases) that patients should factor into total treatment expense.

The FDA label states: "Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" 1. Delaware physicians must weigh the 10-year ASCVD risk score against the 10-year FRAX fracture probability when deciding whether romosozumab is appropriate.

Step-by-Step: Getting Evenity Covered in Delaware

For patients and prescribers navigating the approval process, the sequence matters. Start with a current DEXA scan (within 24 months) documenting T-score at hip or spine. Obtain FRAX calculation showing 10-year risk. Document prior bisphosphonate trial (minimum 12 months of adherence, or documented intolerance/contraindication). Complete cardiovascular screening per label requirements. Submit prior authorization with all documentation simultaneously rather than in pieces.

If denied, request the insurer's peer-to-peer review within 5 business days. Cite the Endocrine Society guideline's "very high fracture risk" criteria and the ARCH data. Delaware Insurance Commissioner regulations require insurers to process external reviews within 45 days for non-urgent cases 8.

The American Association of Clinical Endocrinology's 2020 position statement noted: "Pharmacologic therapy should be initiated promptly in patients at very high fracture risk, with anabolic agents as first-line options" 9. This language supports first-line romosozumab use without prior bisphosphonate failure.

What Happens After 12 Months of Romosozumab

Romosozumab is approved for only 12 monthly doses. Bone density gains reverse rapidly after discontinuation unless followed by an antiresorptive agent. The standard sequence: 12 months of romosozumab followed by denosumab (Prolia, every 6 months) or a bisphosphonate.

This sequencing adds cost beyond the initial $21,900. Denosumab adds approximately $3,200-$3,600 annually. Oral alendronate adds under $200 annually. Patients should plan for the full treatment arc, not just the romosozumab phase, when budgeting.

Data from the FRAME extension showed patients who received romosozumab for 12 months followed by denosumab for 12 months gained 11.3% in lumbar spine BMD from baseline 7. Discontinuing all therapy after romosozumab without antiresorptive consolidation leads to bone loss within 12 months that erases approximately half the gains.

Confirm with your prescriber that a post-romosozumab antiresorptive plan is in place before starting therapy, and verify insurance coverage for both phases simultaneously to avoid a gap in treatment.